MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. MannKind will initiate a tender offer to purchase all outstanding shares of scPharmaceuticals' common stock for $5.35 per share in cash. This acquisition will integrate scPharmaceuticals' commercial and medical capabilities into MannKind's existing infrastructure. The transaction includes a strategic financing agreement with Blackstone, providing an additional $175 million to support the acquisition. Additionally, MannKind will repay and extinguish all scPharmaceuticals' outstanding debt under its credit facility with Perceptive, with the repayment and buyout amount estimated at $81 million. This move is expected to enhance MannKind's market opportunities, particularly with the potential submission of the FUROSCIX ReadyFlow Autoinjector for sNDA in Q3 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.